Graft-Versus-Host Disease Excellence Forum

Graft-Versus-Host Disease

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Efficacy of Omidubicel vs Standard Umbilical Cord Blood Transplantation for Patients With GVHD

03/09/2022

Mitchell E. Horwitz, MD, discusses results from a phase 3 trial evaluating the efficacy of omidubicel compared to standard umbilical cord blood transplantation for patients with GVHD.

Mitchell E. Horwitz, MD,...

03/09/2022

Oncology

Videos

GVHD Outcomes of Busulfan Plus Fludarabine for Older Patients With Hematologic Malignancies

03/03/2022

Uday R Popat, MD, overviews the long-term disease outcomes from a phase 2 prospective clinical trial on myeloablative fractionated busulfan with fludarabine in older patients with hematologic malignancies.

Uday R Popat, MD, overviews the...

03/03/2022

Oncology

Interview

Post-Transplantation Cyclophosphamide Plus Sirolimus Associated With Lower Risk of Chronic GVHD

02/24/2022

Madiha Iqbal, MD, MBBS, spoke on findings from a study evaluating post-transplantation cyclophosphamide plus sirolimus and how it is associated with a lower risk of chronic GVHD.

Madiha Iqbal, MD, MBBS, spoke on...

02/24/2022

Oncology

Videos

Dr Iqbal Highlights Calcineurin Inhibitor Free GVHD Prophylaxis for Patients Undergoing Allo-HCT

02/22/2022

Madiha Iqbal, MD, MBBS, discusses calcineurin inhibitor free GVHD prophylaxis for patients undergoing matched-related and matched-unrelated donor allogeneic HCT.

Madiha Iqbal, MD, MBBS,...

02/22/2022

Oncology

Videos

Orca-T Demonstrates Reduced Instances of GVHD for Hematologic Malignancies

01/24/2022

Dr Meyer on how Orca-T, an investigational cell therapy, led to high GVHD- and relapse-free survival following myeloablative conditioning for hematologic malignancies, presented at ASH 2021.

Dr Meyer on how Orca-T, an...

01/24/2022

Oncology

Videos

Dr Hamilton Talks Tacrolimus Plus Mexotrexate With or Without Mycophenolate Mofetil for GVHD

01/20/2022

Betty Hamilton, MD, shares results from a trial comparing tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate and mycophenolate mofetil for the prevention of GVHD after allogeneic HCT, presented at ASH 2021.

Betty Hamilton, MD, shares...

01/20/2022

Oncology

Videos

Human Chorionic Gonadotropin/Epidermal Growth Factor as Treatment for aGVHD

01/13/2022

Shernan Holtan, MD, provides overview of a phase 2 study on human chorionic gonadotropin and epidermal growth factor as treatment for patients with aGVHD. These data were presented at ASH 2021.

Shernan Holtan, MD, provides...

01/13/2022

Oncology

Videos

Dr Lazaryan Discusses ROCKstar Study Results for cGVHD

08/05/2021

Aleksandr Lazaryan, MD, MPH, PhD, discusses the phase 2b ROCKstar study of belumosudil in patients with cGVHD after ≥2 prior lines of therapy.

Aleksandr Lazaryan, MD, MPH,...

08/05/2021

Oncology

Conference Insider

Ibrutinib Plus Prednisone Improves Patient-Reported Outcomes in cGVHD

07/01/2021

Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.

Ibrutinib given in combination...

07/01/2021

Oncology

Videos

Aleksandr Lazaryan, MD, Discusses Belumosudil as Effective Therapy for cGVHD

06/21/2021

Dr Lazaryan discusses a phase 2a clinical trial of belumosudil in patients with pretreated cGVHD.

Dr Lazaryan discusses a phase 2a...

06/21/2021

Oncology

Recent News

News

Tacrolimus and Reduced-Dose Methotrexate Combined With Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease

09/28/2023

Gina Tomaine

Tacrolimus plus a reduced-dose of methotrexate combined with mycophenolate for GVHD prevention demonstrated a more favorable toxicity profile compared with the standard-of-care, according to a phase 3 trial.

Tacrolimus plus a reduced-dose...

09/28/2023

Oncology

Conference Insider

Ibrutinib Plus Prednisone Improves Patient-Reported Outcomes in cGVHD

07/01/2021

Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.

Ibrutinib given in combination...

07/01/2021

Oncology

News

ROCK2 Inhibition With Belumosudil Yields Promising Results for cGVHD

05/10/2021

Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.

Belumosudil produces high...

05/10/2021

Oncology

News

Ruxolitinib Active, Well-Tolerated in Patients With Steroid-Refractory Acute GVHD

06/23/2020

In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.

In a phase 2 clinical trial,...

06/23/2020

Oncology

News

Improved Efficacy Outcomes With Ruxolitinib for GVHD After Allogeneic Transplantation

05/13/2020

Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Ruxolitinib significantly...

05/13/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology